Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: Benefit of a novel nonviral vector, cationized dextran

Tissue Engineering

Volumn 13, Issue 2, 2007, Pages 313-322

  Jo, Jun Ichiro ^a   Nagaya, Noritoshi ^b   Miyahara, Yoshinori ^b   Kataoka, Masaharu ^b   Harada Shiba, Mariko ^b   Kangawa, Kenji ^b   Tabata, Yasuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DNA; GENETIC ENGINEERING; GROWTH KINETICS; POLYSACCHARIDES; PROTEINS; TRANSPLANTATION (SURGICAL);

ADRENOMEDULLIN (AM); GROWTH FACTORS; MYOCARDIAL INFARCTION; STEM CELLS;

BIOMEDICAL ENGINEERING;

ADRENOMEDULLIN; ANGIOGENIC FACTOR; APOPTOSIS INHIBITOR; DEXTRAN; DNA; POLYSACCHARIDE; SPERMINE;

ARTICLE; CATION TRANSPORT; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; GENETIC ENGINEERING; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TISSUE ENGINEERING;

ADRENOMEDULLIN; ANIMALS; CATIONS; DEXTRANS; DNA; DRUG CARRIERS; GENETIC ENHANCEMENT; GENETIC VECTORS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; RATS; RATS, INBRED LEW; RECOVERY OF FUNCTION; TRANSFECTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VIRUSES;

RATTUS;

EID: 33847073124     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.0133     Document Type: Article

References (37)

1. Shah P.B., Losordo D.W. Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Adv Genet 54, 339, 2005.
2. Hennekens C.H. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 97, 1095, 1998.
3. Lee N, Thorne T, Losordo D.W., et al. Repair of ischemic heart disease with novel bone marrow-derived multipotent stem cells. Cell Cycle 4, 861, 2005.
4. Schratzberger P, Kirchmair R, Vale P.R., et al. Therapeutic angiogenesis by gene transfer in critical limb and myocardial ischemia. Curr Pharm Des 9, 1041, 2003.
5. Kawamoto A, Tkebuchava T, Yamaguchi J, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia: Circulation 107, 461, 2003.
6. Yoon Y.S., Johnson I.A., Park J.S., et al. Therapeutic myocardial angiogenesis with vascular endothelial growth factors. Mol Cell Biochem 264, 63, 2004.
7. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143, 1999.
8. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103, 697, 1999.
9. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109, 337, 2002.
10. Toma C, Pittenger M.F., Cahill K.S., et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93, 2002.
11. Wang J.S., Shum-Tim D, Galipeau J, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 120, 999, 2000.
12. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104, 1046, 2001.
13. Kobayashi T, Hamano K, Li T.S., et al. Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. J Surg Res 89, 189, 2000.
14. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7, 430, 2001.
15. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112, 1128, 2005.
16. Gafni Y, Turgeman G, Liebergal M, et al. Stem cells as vehicles for orthopedic gene therapy. Gene Ther 11, 417, 2004.
17. Chang S.C., Chuang H.L., Chen Y.R., et al. Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration. Gene Ther 10, 2013, 2003.
18. Park J, Ries J, Gelse K, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10, 1089, 2003.
19. Turgeman G, Pittman D.D., Muller R, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med 3, 240, 2001.
20. Mangi A.A., Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9, 1195, 2003.
21. Sato H, Kuwashima N, Sakaida T, et al. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 12, 757, 2005.
22. Studeny M, Marini F.C., Dembinski J.L., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96, 1593, 2004.
23. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192, 553, 1993.
24. Miyashita K, Itoh H, Sawada N, et al. Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo. FEBS Lett 544, 86, 2003.
25. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90, 1243, 2002.
26. Kim W, Moon S.O., Sung M.J., et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. Faseb J 17, 1937, 2003.
27. Sata M, Kakoki M, Nagata D, et al. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 36, 83, 2000.
28. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109, 242, 2004.
29. Tokunaga N, Nagaya N, Shirai M, et al. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation 109, 526, 2004.
30. Nagaya N, Mori H, Murakami S, et al. Adrenomedullin: angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol 288, R1432, 2005.
31. Hermanson G.T. Bioconjugate Techniques. San Diego, CA: Academic Press, 1996.
32. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101, 498, 2000.
33. Nagaya N, Nishikimi T, Yoshihara F, et al. Cardiac adreno-medullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol Regul Integr Comp Physiol 278, R1019, 2000.
34. Chien Y.W., Barbee R.W., MacPhee A.A., et al. Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am J Physiol 254, R185, 1988.
35. Messina L.M., Podrazik R.M., Whitehill T.A., et al. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat. Proc Natl Acad Sci U S A 89, 12018, 1992.
36. Jo J, Yamamoto M, Okazaki A, et al. Enhancement of in vitro gene transfection efficiency of adult stem cells by cationized polysaccharide derivatives. Polymer Prepr Jap 54, 2142, 2005.
37. Klotz U, Kroemer H. Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet 12, 123, 1987.